Skip to content

PreTerm RNA in Maternal Serum

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02521337
Enrollment
150
Registered
2015-08-13
Start date
2016-01-31
Completion date
2018-01-31
Last updated
2016-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth

Brief summary

Preterm birth is defined as a birth occurring before the completion of 37 weeks gestation. The incidence of preterm birth in Israel in the last years is around 7-8%. Despite various diagnostic modalities as well as newly therapeutic approaches the incidence of preterm birth remains unchanged and is considered to be the leading cause of neonatal morbidity and mortality. In the last decade, small RNAs have emerged as an important player in both physiological and pathophysiological responses. These single strands, non-coding regulatory RNA molecules are responsible for post transcriptional regulation of target genes. Hence, may provide a new opportunity for biomarkers discovery in the field of preterm birth. The main objective of this study is to identify a distinctive expression profile of maternal circulating RNAs that will be used as biomarkers for preterm birth.

Interventions

OTHERobservation

observation

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

1. Women with singleton pregnancy at 26-32 week of gestation with no clinical symptoms of preterm labor. 2. Women with singleton pregnancy 24-34 week of gestation who present to the labor suite with symptoms suspected for preterm labor. 3. Women with singleton pregnancy in term active labor (weeks 37-40).

Design outcomes

Primary

MeasureTime frame
Number of women with preterm labor that present a unique RNA cluster2 years

Countries

Israel

Contacts

Primary ContactDrorith Hochner-Celnikier, MD
Hochner@hadassah.org.il00 972 2 5484400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026